Phase III Immunotherapy Trial for Migraine Shows Positive Results
Medicine, Health Care Phase III Immunotherapy Trial for… Published: November 30, 2017.Released by Thomas Jefferson University (PHILADELPHIA) – A new study of fremanezumab, an immunotherapy that counteracts one of the molecules released during migraine, was found successful in reducing the number of days that chronic migraine sufferers experienced headaches. The results of the phase III clinical trial were published November 29, 2017 in the New England Journal of Medicine. The World Health Organization estimates that
Read More